

## Notice of End of Replacement of Medications

An Act respecting prescription drug insurance  
(chapter A-29.01, s. 60.1)

The Régie de l'assurance maladie du Québec hereby gives notice that it is cancelling the notice of replacement published on its website on [5 May 2016](#) and in force as of 6 April 2016, which authorized temporary use of the following alternative (hereinafter referred to as the “alternative”):

<b>Code</b>	<b>Manufacturer</b>	<b>Generic name, form, strength</b>
99101280		Imipenem/Cilastatin, I.V. Inj. Pd., 500 mg – 500 mg

That alternative was a replacement for the following medication, once again available, which appears on the List of Medications attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan:

<b>Code</b>	<b>Manufacturer</b>	<b>Brand name, form, strength</b>
00717282	Merck	Primaxin, I.V. Inj. Pd., 500 mg – 500 mg

Consequently, use of the alternative is no longer authorized.

This notice has effect from 17 September 2016. Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it, in accordance with section 60.1 of the Act respecting prescription drug insurance.

Québec, 6 October 2016

Original signed by

Chantal Garcia  
Secretary General of the  
Régie de l'assurance maladie du Québec